Inspira Technologies Secures U.S. Patent for ART500 Technology
Inspira Technologies OXY B.H.N. Ltd. (NASDAQ: IINN), a trailblazer in life-support innovations, has recently garnered U.S. patent approval for its groundbreaking ART500 device, a low flow rates extracorporeal oxygenation system. This approval marks a significant milestone, establishing the company's foothold in the estimated $20 billion market for advanced respiratory support systems.
The Significance of the ART500 Patent
This new patent solidifies the core technology of the ART500 device, which is specifically engineered to deliver extracorporeal oxygenation at low flow rates. Such technology is particularly vital for patient safety and the efficiency of treatment. It targets a previously underserved patient demographic—those who may require respiratory assistance but do not necessarily qualify for conventional high-flow ECMO systems, thereby broadening the potential market for Inspira's innovations.
Leadership Insights on the Patent Approval
Dagi Ben-Noon, Chief Executive Officer of Inspira Technologies, highlighted the transformative potential of this patent. He expressed that securing this intellectual property is a vital strategy for the company's future, stating, "This patent has profound business implications for Inspira and for our ability to dominate a market with a potential size of $20 billion. Protecting our intellectual property is crucial, and this approval grants us a distinct competitive edge." He noted that while the ART100 system is already making waves in the market, the ART500 patent enhances their prospects significantly.
Long-Term Vision with Enhanced Intellectual Property
The approved patent will protect Inspira's technology until at least 2043, covering key functionalities, design aspects, and clinical applications of the ART500 system. The company is also actively pursuing additional patent protections across major global markets to bolster its intellectual property portfolio further.
About Inspira Technologies
Inspira Technologies specializes in advanced medical devices focused on respiratory support and real-time blood monitoring solutions. The company's FDA-cleared INSPIRA™ ART100 system is designed for cardiopulmonary bypass and ECMO procedures, serving as the cornerstone for the innovative ART500 system. The ART500 allows for oxygenation while patients remain conscious and spontaneously breathing.
Furthermore, Inspira is advancing its proprietary HYLA™ blood sensor platform, which offers continuous and non-invasive monitoring capabilities. With a strong pipeline of cleared products and a growing intellectual property portfolio, Inspira Technologies is strategically positioned as a key player in the life-support and MedTech industries, gearing up for potential strategic partnerships as the field evolves.
Frequently Asked Questions
What is the ART500 technology?
ART500 is an extracorporeal oxygenation system that provides support at low flow rates, designed specifically for patients who may not be critically ill.
What impact does the new patent have on Inspira Technologies?
The patent strengthens Inspira's competitive position, allowing the company to protect its innovations and expand into a $20 billion market for respiratory support.
How long does the patent protection last?
The patent is expected to provide protection until at least the year 2043, covering essential claims regarding the technology's functionality and applications.
What other products does Inspira offer?
Besides the ART500 system, Inspira Technologies also offers the INSPIRA™ ART100 system and is developing the HYLA™ blood sensor platform for advanced monitoring solutions.
What future plans does Inspira have regarding patents?
Inspira aims to pursue additional patents in key jurisdictions worldwide to further enhance its intellectual property rights.
